Although the β,1-adrenoreceptor (AR) Gly389Arg and α2C-AR Del322-325 gene variants are associated with the response to β-AR-blocker therapy, whether this effect is associated with the risk for heart failure, or the severity or progression of heart failure is uncertain. Here, AR is linked to heart failure.